Long-lasting ischemia can result in cell loss; however, repeated episodes of brief ischemia increase the resistance of the heart against deleterious effects of subsequent prolonged ischemic insult and promote cell survival. Traditionally, it is believed that the supply of blood to the ischemic heart is associated with release of cytokines, activation of inflammatory response and induction of necrotic cell death. In the past few years, this paradigm of passive necrosis as an uncontrolled cell death has been re-examined and the existence of a strictly regulated form of necrotic cell death, necroptosis, has been documented. This controlled cell death modality, resembling all morphological features of necrosis, has been investigated in different types of ischemia-associated heart injuries. The process of necroptosis has been found to be dependent on the activation of RIP1-RIP3-MLKL axis, which induces changes leading to the rupture of cell membrane. This pathway is activated by TNF-α, which has also been implicated in the cardioprotective signaling pathway of ischemic preconditioning. Thus, this review is intended to describe the TNF-α mediated signaling leading to either cell survival or necroptotic cell death. In addition, some experimental data suggesting a link between heart dysfunction and the cellular loss due to necroptosis are discussed in various conditions of myocardial ischemia.
Introduction
In spite of the increased knowledge for the promotion of positive effects of a healthy lifestyle as well as effective therapeutical approaches, the mortality of patients with ischemia-associated heart diseases is on the rise and thus it is one of the leading causes of death worldwide. Depending on its duration, ischemia can induce reversible or irreversible cellular injury, which phenotypically manifests as cardiac contractile dysfunction, lifethreatening arrhythmias, heart failure and cardiacfibrosis. In contrast, brief periods of ischemia prior to a prolonged ischemic insult have been recognized as a cardioprotective intervention. This non-pharmacological phenomenon called "ischemic preconditioning (IPC)" is known to reduce the infarct size as well as severity of other end-points of ischemic injury via the activation of intrinsic cell-survival programs (Jennings and Reimer 1991; Kloner and Braunwald 1980; Opie 1987) . Thus, the responses of the heart to ischemia are considered to be bimodal of nature. While short episodes of ischemia induce adaptation to the injury, a long ischemic insult is deleterious to the heart. With respect to prognosis, one of the key factors determining the function and overall viability of the previously ischemic cardiac tissue is the cellular loss. Since adult cardiomyocytes are terminally differentiated and have little potential for proliferation and self-renewal, the number of functional cardiac cells in the postnatal myocardium is considered to dictate the ability of the heart to mediate the excitationcontraction coupling process and adapt to the injury/stress including ischemic insult (Kajstura et al. 1998; Smith and Zhang 2015) .
Until recently, apoptosis and necrosis have been reported to be involved in various types of the ischemia-induced cardiac pathologies. Apoptosis, as an ATP-dependent process, has been proposed to be activated mainly during the post-ischemic restoration of blood flow (reperfusion) while necrosis, a passive process, is believed to be associated with cardiac injury during ischemia when energy production is suppressed (Fliss and Gattinger 1996 Kajstura et al. 1996; Zhao et al. 2000) . Nonetheless, the relative extents of apoptosis and necrosis in certain types of acute ischemia (global versus regional) are still a matter of intensive investigation. Furthermore, the cell loss underlying heart failure due to the myocardial infarction has been examined extensively; however, the number of apoptotic positive cells has been reported to be rather low Kang and Izumo 2000; Mani 2008) .
Over the past few years, the knowledge about passive necrosis, traditionally considered an accidental process, has advanced considerably and a new form of regulated necrosis, called "necroptosis", has gained acceptance among several biologists and cardiologists . Both passive necrosis and necroptosis are characterized by membranedisruption, cell integrity loss, mitochondrial dysfunction and inflammatory response in the surrounding environment; however, these processes differ in their regulation.
While passive necrosis is an unregulated process, necroptosis has been shown to be strictly regulated by certain signaling pathways; this has been discussedin the following sections.
Mechanisms of necroptotic cell death and role of TNF-α in cell`s decision to either die or promote prosurvival program
Necroptosis is a form of programmed necrosis dependent on receptor-interacting protein kinase-1 (RIP1) and/or receptor interacting protein kinase-3 (RIP3). It has been reported to be induced by stimulation of several death receptors (TNFR1, Fas, TRAIL-R, DR6 and T cell receptor) as well as some other triggers not associated with these stimuli (Moquin et al. 2010; Strilic et al. 2016) . Current understanding of molecular mechanisms of necroptosis is largely based on experiments involving TNFR1 ligation. Normally, stimulation of TNFR1 by TNF-α can lead into two distinct outcomes, namely stimulation of cell survival or and occurrence of cell death. The trigger for the particular TNF-α-mediated pathway is D r a f t 3 determined by posttranslational modification of RIP1 (Figure 1 ). In fact, polyubiquitination of RIP1 (especially at residue Lys 377 in membrane-bound complex I assembled transiently) after TNFR1 activation is required for RIP1 to serve as a scaffold for the recruitment of transforming growth factor beta-activated kinase 1 (TAK1) and nuclear factor-kappa-B essential modulator (NEMO). Both TAK1 and NEMO are involved in cell survival signaling through nuclear factor kappa B (NF-κB) (Ea et al. 2006; Li et al. 2006; O'Donnell et al. 2007 ). This scaffolding function of RIP1 is independent of its kinase activity, unlike its role in cell death signaling (Degterev et al. 2005 (Degterev et al. , 2008 . The degree of activation of NF-κB-dependent pathways after TNFR1 stimulation and the extent of RIP1 ubiquitination are finetuned by different ubiquitin-modifying enzymes, such as cellular inhibitor of apoptosis (cIAP1/2), A20 and cylindromatosis (CYLD) (Moquin et al. 2010; Vanlangenakker et al. 2010 Vanlangenakker et al. , 2011 . On the other hand, in the case of increased activity of CYLD or in the absence of polyubiquitination due to cIAP1/2 loss leading into deubiquitination of RIP1, complex I internalizes and turns into cell death-promoting complex II by primarily recruiting procaspase-8 (Micheau and Tschopp 2003; Moquin et al. 2010; Schneider-Brachert et al. 2004; Vanlangenakker et al. 2010 ).
With the context of uninhibited caspase-8 activity, procaspase-8 homodimerizes,
cleaves itself into an active form and mediates the apoptotic cascade while at the same time it inhibits necroptosis by cleaving RIP1 and RIP3 (Declerq et al. 2009; Feng et al. 2007; Moquin et al. 2010) . When the caspase-8 activity is insufficient, the uncleaved RIP1 retains its kinase activity thereby promoting autophosphorylation of other molecules of RIP1 and subsequent phosphorylation of RIP3 inducing necroptosis propagation (Cho et al. 2009 ). Once RIP3 is phosphorylated, mixed-lineage kinase domain-like protein (MLKL), a downstream of RIP3 (considered to be the most important terminal protein of necroptosis so far) is recruited to the RIP1-RIP3 complex (Sun et al. 2012; Wu et al. 2012 (Sun et al. 2012; Quarato et al. 2016; Wang et al. 2014) . Current evidence suggests that once MLKL oligomers are assembled in membranes, these essentially act as either non-specific pores ( Chytilova et al. 2015) . Thus, it is plausible that a balance between TNF-α-mediated beneficial and detrimental effects strongly depends on its actual tissue and plasmatic levels.
While high levels of TNF-α are associated with cardiac injury, a low concentration may trigger prosurvival signaling. Because TNF-α is also produced by tissue, besides by cells of the immune system, the contribution of TNF-α from autocrine, paracrine and juxtacrine origin can participate in the final decision of cardiac cells to undergo either of the pathways. Thus, it could be hypothesized that a response of the myocardium to TNF-α produced by various heart cells can be different. In fact, the inflammatory cytokines, inlcuding TNF-alpha, synthetized by fibroblasts rather than by cardiomyocytes per se can undesirably affect cardiac cell morphology, and contraction capability (LaFramboise et al. 2007) . A critical role of certain cells synthetizing TNF-α has also been reported in a study of Lambertsen et al. (2009), who showed that the microglial not leukocyte-derived cytokine determines the survival of endangered neurons in cerebral ischemia. A dual role of TNF-α, highlighting the divergent effects of certain levels of this molecule, is also supported by findings of a clinical study using infliximab (a TNF-α antibody), which at a higher dose (10 mg/kg), but not a lower one (5 mg/kg), worsened the end-points (Chung et al. 2003) .
Evidence of necroptosis in cardiac tissue subjected to ischemia and ischemia-induced necroptotic loss of cardiac cells
A wide spectrum of diseases (gout, sclerosis multiplex, amyotropic lateral sclerosis, non-alcoholic steatohepatitits, atherosclerosis, aortic aneurysms and chronic obstructive pulmonary disease) (Afonso et al. 2015; Desai et al. 2016; Mizumura et al. 2014; Meng et al. 2015; Ofengeim et al. 2015; Re et al. 2014; Wang et al. 2015) , as well as disorders associated with ischemic injury have been found to be positive for necroptosis (Linkermann et al. 2012 , D r a f t 6 2013; Northington et al. 2011; Wen et al. 2016 ). In accordance (as discussed below), necroptosis inhibition following acute myocardial I/R injury has been proven to exert beneficial effects in both in vivo and ex vivo animal models. In fact, Nec-1, a widely used necroptosis inhibitor, given to mice intraperitoneally reduced the size of infarction, while
Nec-1i, its inactive analogue, did not show any effect (Smith et al. 2007 ). Similar results were also reported after intravenous Nec-1 application in mice (Lim et al. 2007; Oerlemans et al. 2012 ) as well as pigs (Koudstaal et al. 2015) . In ex vivo experiments, hearts perfused with Nec-1 were protected from cell death and exhibited reduced infarct development (Dmitriev et al. 2013; Koshinuma et al. 2014; Smith et al. 2007 ). Furthermore, the work by Luedde et al.
(2014) has demonstrated that mice deficient in RIP3, a critical member of the necroptotic cascade, show a significantly improved ejection fraction, less hypertrophy and inflammatory response after permanent coronary artery ligation. These observations are concordant with a very recent study utilizing the same animal knockout model (Zhang et al. 2016) . To extend this knowledge, we performed some studies investigating the extent of necroptotic cell death in both ventricles of failing hearts due to irreversible ischemia and in hearts adapted to an ischemic insult. Ischemic cardiomyopathy was found to be developed during 42 days in rats after 1-hour of the coronary ligation whereas ischemic preconditioning induced by one cycle of 5 min of ischemia and 5 min of reperfusion protected the heart following ischemia for 30 min and reperfusion for 40 min. In the case of ischemic cardiomyopathy, the heart failure was characterized by contractile dysfunction as evidenced by depressed fractional shortening (Figure 2) . In this experimental model, the expression of RIP1 and RIP3 was increased in the left ventricle; however, the expression of these markers in the right ventricle was comparable between groups (data not shown). Importantly, the terminal necroptotic protein MLKL was found to be upregulated in the left ventricle of failing hearts indicating the presence of necroptotic cell injury (Table 1) . It should be, however, pointed out that the necroptotic D r a f t cascade involved in this condition needs to be supported by detection of phoshorylated species of MLKL. In spite of this limitation, the results of this study have indicated the relevance of necroptosis in ischemic cardiomyopathy, which may underlie death of cardiomyocytes and mechanical dysfunction of the heart. On the other hand, ischemic preconditioning, which is known to improve the post-ischemic recovery of the left ventricular function (Figure 3 ), failed to modulate the necroptotic markers. In fact, the ventricular tissue samples from the preconditioned hearts showed no changes in protein expression of RIP1, RIP3 and MLKL as compared to those from the non-preconditioned hearts. It should be noted that the hearts subjected to I/R were characterized by increased presence of some of these necroptotic markers (Table 2) .
Since necroptosis is a relatively recently defined form of cell death, the mechanisms of however, it retains the ability to inhibit IDO (Degterev et al. 2013; Takahashi et al. 2012 ). In addition, we have recently reported that Nec-1 likely exerts off-target pharmacodynamic effects modulating basal heart function . In fact, after a bolus application, Nec-1 increased systolic and diastolic blood pressure as well as heart rate. Likewise, analysis of ECG changes revealed the capability of Nec-1 to promote faster conduction of the impulses through atria to the ventricles. To avoid misinterpretation of data which may arise from these off-target effects, the use of an inhibitor being selective for RIP1 with no additional action is highly warranted. Nec-1s, a Nec-1 analogue inhibiting RIP1 while not affecting IDO or other intracellular molecules, seems to represent the most specific and appropriate pharmacological tool for the study of necroptosis in animals (Degterev et al. 2013; Takahashi et al. 2012) .
Conclusions
Ischemia, depending on the duration and type, can act as a bimodal process as it D r a f t induces adaptive response for the activation of survival signaling or produces reversible/irreversible injury leading to a significant loss of cardiac cells. Although passive necrosis and apoptosis are generally associated with ischemia-mediated cardiac injury, necroptosis, which shares certain features of both these forms of cell death, has recently been reported to determine the extent of viable myocardium after ischemic insults. In fact, the major necroptotic markers, RIP3 and MLKL, have been documented being upregulated in hearts subjected to acute ischemia followed by reperfusion. Likewise in post-infarcted failing rat hearts, these upregulated markers have been suggested to contribute to adverse cardiac remodeling and underlie disturbances in contractile function. In contrast, the inhibition of RIP1 by necrostatins has been reported to be capable of mitigating the injury and preventing the contractile dysfunction. Interestingly, a brief episode of ischemia before a more prolonged ischemic insult has been shown to limit the infarct size and abolish cardiac stunning; however, this ischemic preconditioning did not modulate the expression of these pronecroptotic proteins. Thus, it appears that the elevated levels of RIP3 and MLKL are the only definite criteria to distinguish necroptosis from other forms of cell death due to passive necrosis and apoptosis. It can also be concluded that cardiac tissue injured by acute ischemia, as well as post-infarction cardiomyopathy is positive for necroptosis while the heart subjected to ischemic preconditioning is unlikely to be directly protected from necroptosis. However, with respect to the progression of necroptosis, these findings should ideally be supported by immunohistochemical and/or immunoprecipitation investigations. From the foregoing discussion it is evident that necroptosis plays an important role in the loss of cardiac cells subjected to various types of ischemic insults; however, further studies are needed to investigate factors determining the exact mechanisms of necroptosis under several pathological conditions. Likewise, it is also important to investigate the exact role of TNF-α- The results are expressed as means ± SEM from 6 hearts. Statistical analysis was performed by 1-way ANOVA followed by Student's t-test. C -control perfused group; IR -group subjected to ischemia/reperfusion injury; IPC -group subjected to ischemic preconditioning followed by prolonged ischemia/reperfusion. *P <0.05 vs C. Each bar represents mean ± SEM. Statistical analysis was performed by 1-way ANOVA followed by Student's t-test. N = 9-12 per group. C -control group; *P < 0.05 vs. C.
